Welcome
Support Centre
11 February 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
The Effect of Coating of the Cardiopulmonary Bypass Circuit with Poly-2-methoxyethylacrylate (PMEA) on the Systemic Inflammatory Response
ISRCTN ISRCTN42608249
ClinicalTrials.gov identifier
Public title The Effect of Coating of the Cardiopulmonary Bypass Circuit with Poly-2-methoxyethylacrylate (PMEA) on the Systemic Inflammatory Response
Scientific title
Acronym N/A
Serial number at source N0295142271
Study hypothesis To compare outcomes in patients undergoing coronary artery bypass grafting using either standard non-coated cardiopulmonary circuits or circuits in which all components have been coated with PMEA.
Lay summary
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Surgery: Cardiopulmonary bypass
Participants - inclusion criteria Patients undergoing first-time, isolated, elective coronary artery bypass grafting at UHCW, who have not taken any anti-platelet medication for five days previous to the operation, will be eligible for the study. We aim to recruit 40 patients.
Participants - exclusion criteria 1. Patients undergoing repeated surgery
2. Patients undergoing emergency surgery
3. Patients taking antiplatelet medication
Anticipated start date 19/04/2004
Anticipated end date 30/10/2004
Status of trial Completed
Patient information material
Target number of participants 40
Interventions Prospective randomised controlled trial.
Primary outcome measure(s) Post-operative blood loss and transfusion requirements, pulmonary, renal, neurological, cardiac and infective complications during hospitalisation, duration of ICU and hospital stay and thirty day mortality. The magnitude of the inflammatory response will be assessed by measuring plasma levels of inflammatory mediators. Platelet function and coagulation will be assessed by flow cytometry and thromboelastography.
Secondary outcome measure(s) Not provided at time of registration
Sources of funding University Hospitals Coventry and Warwickshire NHS Trust (UK)
NHS R&D Support Funding (UK)
Trial website
Publications
Contact name Mr  Moninder  Bhabra
  Address Cardiothoracic Unit, 3rd floor
UHCW NHS Trust
Clifford Bridge Road
  City/town Coventry
  Zip/Postcode CV2 2DX
  Country United Kingdom
Sponsor Record Provided by the NHSTCT Register - 2005 Update - Department of Health (UK)
  Address The Department of Health
Richmond House
79 Whitehall
  City/town London
  Zip/Postcode SW1A 2NL
  Country United Kingdom
  Tel +44 (0)20 7307 2622
  Fax +44 (0)20 7307 2623
  Email dhmail@doh.gsi.org.uk
  Sponsor website: http://www.dh.gov.uk/Home/fs/en
Date applied 30/09/2005
Last edited 10/07/2009
Date ISRCTN assigned 30/09/2005
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central